Press release
Land Rover LRX Hybrid Concept unveiled
Land Rover unveiled a vision of its future recently (January 13, 2008) at the North American International Auto Show (Detroit Auto Show) with the world debut of the LRX hybrid concept - a bold evolution of Land Rover design that indicates the brand’s progressive shift into new areas of the market while remaining true to its core values. As the company prepares to celebrate its 60th anniversary during 2008, the three-door LRX, with its more compact size, lighter weight and sustainability-focused technologies, clearly addresses the needs of a changing world and offers the potential of 120 g/km CO2 emissions.For more details contact Island Lincoln Mercury Jaguar Land Rover, the leading dealership for new and pre-owned Lincoln, Mercury, Jaguar and Land Rover vehicles at Merritt Island, Florida (FL). Visit http://www.luxurychallenge.com or call 866-415-9833.
"The LRX concept delivers the powerful message that we are as serious about sustainability as we are confident about the continuing relevance and desirability of our vehicles," Land Rover’s Managing Director Phil Popham said. "LRX is in every respect a Land Rover, but it’s a very different Land Rover”.
LRX is described as a cross-coupé and dramatically extends the scope of what Land Rover represents. LRX has been conceived as a premium vehicle, designed to appeal to new customers in the luxury and executive sector – those who want many of the benefits of an SUV and the presence of a larger vehicle, but in a more compact package.
Its compact size is one of its greatest assets, which will appeal to anyone who wants the versatile ability of an agile SUV with the cachet of the Land Rover name. In addition, its lower weight and the reduced aerodynamic drag resulting from the smaller frontal area would help give significant gains in fuel efficiency and reduced CO2 emissions.
LRX is conceived as a highly fuel-efficient, U.S. Federal-specification, 2.0-liter, turbodiesel hybrid, capable of running on bio-diesel. In combination with other Land Rover technologies, this powertrain could reduce fuel consumption by as much as 30 percent compared with other SUVs of comparable size, and reduce emissions to approximately 120 g/km.
The design of LRX was developed entirely in-house by Gerry McGovern’s team, driven by a passion to create a vehicle that truly represents Land Rover’s future thinking. The interior of the LRX concept clearly demonstrates how a compact Land Rover can still be roomy, practical, versatile – and sophisticated. Although LRX is compact, clever use of space makes it impressively roomy, and many neat design touches maximize its practicality.
For more details contact Island Lincoln Mercury Jaguar Land Rover, the leading dealership for new and pre-owned Lincoln, Mercury, Jaguar and Land Rover vehicles in Merritt Island, Florida (FL). Island Lincoln Mercury Jaguar Land Rover offers several features at its dealership, such as Finance Specials, Weekend Specials, New and Used Vehicle Specials, Pre Owned Specials and Lease Specials. Please visit the website at http://www.luxurychallenge.com for more details.
Contact: Island Lincoln Mercury Jaguar Land Rover
1850 East Merritt Island Causeway
Merritt Island, FL 32952
Ph: 866-415-9833
Website: http://www.luxurychallenge.com
Island Lincoln Mercury Jaguar Land Rover
1850 East Merritt Island Causeway
Merritt Island, FL 32952
Ph: 866-415-9833
Island Lincoln Mercury, the leading auto dealer in Merritt Island, Florida, has an unbeatable and exhilarating selection of new, certified pre-owned and used Lincoln, Mercury, Jaguar and Land Rover vehicles at their dealership in Brevard County.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Land Rover LRX Hybrid Concept unveiled here
News-ID: 36496 • Views: …
More Releases for LRX
Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Insight 2025: Gene Silence …
DelveInsight's "Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025" provides an in-depth evaluation of the emerging treatment landscape for this progressive, multisystem, and life-threatening condition caused by pathogenic mutations in the TTR gene. Manifesting as peripheral neuropathy, cardiomyopathy, or a mixed phenotype, hATTR remains underdiagnosed and undertreated globally despite advances in genetic testing and disease awareness.
The 2025 pipeline underscores transformative momentum in TTR gene-silencing therapies, CRISPR-based gene editing, and next-generation…
Familial Chylomicronemia Syndrome Market Size in the 7MM was ~USD 15 million in …
DelveInsight's "Familial Chylomicronemia Syndrome (FCS) Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Key Takeaways from the Familial Chylomicronemia Syndrome Market Research Report
• The expected launch of therapies and better diagnosis will lead to…
Acromegaly Pipeline Insights and Clinical Trials Report 2023
DelveInsight's, "Acromegaly Pipeline Insight 2023" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Acromegaly pipeline landscape. It covers the Acromegaly pipeline drug profiles, including Acromegaly clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Acromegaly Pipeline Report
• Over…
Acromegaly Pipeline| 15+ Key Players & 15+ Pipeline Drugs | FDA, EMA, and PMDA A …
DelveInsight's, "Acromegaly Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acromegaly pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Acromegaly Pipeline Insight report, a detailed description of the drug…
Familial Lipoprotein Lipase Deficiency Pipeline Assessment - FDA, EMA, and PMDA …
DelveInsight's Familial Lipoprotein Lipase Deficiency Pipeline Insight, 2022 report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in the Familial Lipoprotein Lipase Deficiency pipeline landscape
It covers the Familial Lipoprotein Lipase Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Familial Lipoprotein Lipase Deficiency therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
Transthyretin Amyloidosis Treatment Market Exhibit Skyrocketing Expansion During …
Hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis are two main types of transthyretin amyloidosis. hATTR is further classified into Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC). Wild type variant (ATTRwt) predominantly affects the heart.
Transthyretin amyloidosis is a result of transthyretin produced by the liver and forms dimers, followed by monomers. Monomers aggregate to form amyloid fibrils, which are deposited in organs such as heart, nervous system,…